Although patients in this study were on first-line treatment, osimertinib was initially approved for second-line or later treatment of sensitizing EGFR-mutated NSCLC after confirmation of the acquired resistant mutation on exon 20 T790M.31, 32, 33 Therefore, studies to confirm the efficacy of the combination of osimertinib and bevacizumab were conducted in patients with T790M-positive NSCLC who had developed resistance to the preceding first- or second-generation EGFR TKI monotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.